Researchers halted a trial in Africa designed to determine whether a daily dose of a pill containing 2 antiretroviral drugs would help prevent HIV infection in women after an interim assessment showed no evidence that the treatment was protective.
The study, called FEM-PrEP, is a randomized clinical trial of the safety and effectiveness of a daily pill containing emtricitabine and tenofovir (a combination sold under the name Truvada) in preventing HIV infection in women in Africa who are at higher risk of being exposed to HIV. It is one of several trials testing the use of antiretroviral drugs as a prevention strategy in at-risk populations.
Stephenson J. Study Halted: No Benefit Seen From Antiretroviral Pill in Preventing HIV in Women. JAMA. 2011;305(19):1952. doi:10.1001/jama.2011.649
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: